These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12782786)

  • 1. Crystalline monoclonal antibodies for subcutaneous delivery.
    Yang MX; Shenoy B; Disttler M; Patel R; McGrath M; Pechenov S; Margolin AL
    Proc Natl Acad Sci U S A; 2003 Jun; 100(12):6934-9. PubMed ID: 12782786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
    J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
    Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
    J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
    Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
    J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase.
    Shpilberg O; Jackisch C
    Br J Cancer; 2013 Sep; 109(6):1556-61. PubMed ID: 24002601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models.
    Fujimoto-Ouchi K; Sekiguchi F; Tanaka Y
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):211-6. PubMed ID: 11935213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab.
    Chen JL; Wang JY; Tsai YF; Lin YH; Tseng LM; Chang WC; King KL; Chen WS; Chiu JH; Shyr YM
    Menopause; 2013 Jun; 20(6):646-54. PubMed ID: 23340260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system.
    Guilleminault L; Azzopardi N; Arnoult C; Sobilo J; Hervé V; Montharu J; Guillon A; Andres C; Herault O; Le Pape A; Diot P; Lemarié E; Paintaud G; Gouilleux-Gruart V; Heuzé-Vourc'h N
    J Control Release; 2014 Dec; 196():344-54. PubMed ID: 25451545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
    Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
    Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism.
    Adams S; Miller GT; Jesson MI; Watanabe T; Jones B; Wallner BP
    Cancer Res; 2004 Aug; 64(15):5471-80. PubMed ID: 15289357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of cytokine drug delivery systems to the immunotherapy of renal cell carcinoma in mice.
    Marumo K; Oya M; Murai M; Tazaki H
    Int J Urol; 1996 Jan; 3(1 Suppl):S24-7. PubMed ID: 24304015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.
    Spiridon CI; Ghetie MA; Uhr J; Marches R; Li JL; Shen GL; Vitetta ES
    Clin Cancer Res; 2002 Jun; 8(6):1720-30. PubMed ID: 12060609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
    Fujimoto-Ouchi K; Sekiguchi F; Yamamoto K; Shirane M; Yamashita Y; Mori K
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):269-76. PubMed ID: 19904537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
    Rao AV; Schmader K
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.
    Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2006 Aug; 47(8):1342-50. PubMed ID: 16883015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans.
    Mordenti J; Thomsen K; Licko V; Chen H; Meng YG; Ferrara N
    Toxicol Pathol; 1999; 27(1):14-21. PubMed ID: 10367667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
    Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
    Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.
    Brennan PJ; Rodriguez Bouza T; Hsu FI; Sloane DE; Castells MC
    J Allergy Clin Immunol; 2009 Dec; 124(6):1259-66. PubMed ID: 19910036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.